National Comprehensive Cancer Network (NCCN) risk classification in predicting biochemical recurrence after radical prostatectomy: a retrospective cohort study in Chinese prostate cancer patients

Asian J Androl. Nov-Dec 2018;20(6):551-554. doi: 10.4103/aja.aja_52_18.

Abstract

This study aimed to assess the role of the National Comprehensive Cancer Network (NCCN) risk classification in predicting biochemical recurrence (BCR) after radical prostatectomy (RP) in Chinese prostate cancer patients. We included a consecutive cohort of 385 patients with prostate cancer who underwent RP at Fudan University Shanghai Cancer Center (Shanghai, China) from March 2011 to December 2014. Gleason grade groups were applied at analysis according to the 2014 International Society of Urological Pathology Consensus. Risk groups were stratified according to the NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer version 1, 2017. All 385 patients were divided into BCR and non-BCR groups. The clinicopathological characteristics were compared using an independent sample t-test, Chi-squared test, and Fisher's exact test. BCR-free survival was compared using the log-rank test and multivariable Cox proportional hazard analysis. During median follow-up of 48 months (range: 1-78 months), 31 (8.05%) patients experienced BCR. The BCR group had higher prostate-specific antigen level at diagnosis (46.54 ± 39.58 ng ml-1 vs 21.02 ± 21.06 ng ml-1, P= 0.001), more advanced pT stage (P = 0.002), and higher pN1 rate (P < 0.001). NCCN risk classification was a significant predictor of BCR (P = 0.0006) and BCR-free survival (P = 0.003) after RP. As NCCN risk level increased, there was a significant decreasing trend in BCR-free survival rate (Ptrend = 0.0002). This study confirmed and validated that NCCN risk classification was a significant predictor of BCR and BCR-free survival after RP.

Keywords: National Comprehensive Cancer Network risk classification; biochemical recurrence; prostate cancer; radical prostatectomy.

MeSH terms

  • Aged
  • Aged, 80 and over
  • China / epidemiology
  • Cohort Studies
  • Disease-Free Survival
  • Female
  • Follow-Up Studies
  • Guidelines as Topic
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Grading
  • Neoplasm Recurrence, Local / epidemiology
  • Prostate-Specific Antigen / analysis
  • Prostatectomy*
  • Prostatic Neoplasms / epidemiology*
  • Prostatic Neoplasms / metabolism
  • Prostatic Neoplasms / surgery*
  • Retrospective Studies
  • Risk Assessment
  • Survival Analysis

Substances

  • Prostate-Specific Antigen